Who are YL202's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Brenzavvy, Jardiance, Canagliflozin - SGLT2i, A5, Comparator monotherapy empagliflozin, Standard treatment strategy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/yl202.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

YL202 — Competitive Intelligence Brief

YL202 (YL202) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes.

phase 3 SGLT2 inhibitor SGLT2 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

YL202 (YL202) — MediLink Therapeutics (Suzhou) Co., Ltd.. YL202 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
YL202 TARGET	YL202	MediLink Therapeutics (Suzhou) Co., Ltd.	phase 3	SGLT2 inhibitor	SGLT2
Brenzavvy	BEXAGLIFLOZIN	Theracosbio	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2023-01-01
Jardiance	empagliflozin	Boehringer Ingelheim	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2014-01-01
Canagliflozin - SGLT2i	Canagliflozin - SGLT2i	Royal Devon and Exeter NHS Foundation Trust	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
A5	A5	Breath of Life International Pharma Ltd	marketed	SGLT2 inhibitor	SGLT2
Comparator monotherapy empagliflozin	Comparator monotherapy empagliflozin	The George Institute	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Standard treatment strategy	Standard treatment strategy	Fundación para la Investigación del Hospital Clínico de Valencia	marketed	SGLT2 inhibitor	SGLT2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
Takeda · 10 drugs in this class
Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
Hanmi Pharmaceutical Company Limited · 9 drugs in this class
Addpharma Inc. · 9 drugs in this class
GlaxoSmithKline · 7 drugs in this class
AO GENERIUM · 7 drugs in this class
Merck Sharp & Dohme LLC · 7 drugs in this class
Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). YL202 — Competitive Intelligence Brief. https://druglandscape.com/ci/yl202. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab